Serological Cancer Markers

  • Stewart Sell

Part of the Contemporary Biomedicine book series (CB, volume 11)

Table of contents

  1. Front Matter
    Pages i-xv
  2. Stewart Sell
    Pages 1-17
  3. Manfred L. Lüthgens, Peter Oehr
    Pages 19-29
  4. Kazuhisa Taketa
    Pages 31-46
  5. Hanna M. Sikorska, Abraham Fuks, Phil Gold
    Pages 47-97
  6. T. Ming Chu
    Pages 99-115
  7. Doris Balinsky
    Pages 117-133
  8. Torgny Stigbrand, Britta Wahren
    Pages 135-149
  9. Shahla Masood
    Pages 151-192
  10. Peter Oehr, Manfred L. Lüthgens, Qian Liu
    Pages 193-206
  11. Sen-itiroh Hakomori
    Pages 207-232
  12. Daniel F. Hayes, Carlo Tondini, Donald W. Kufe
    Pages 281-307
  13. Caj Haglund, Pentti Kuusela, Peter J. Roberts, Hannu Jalanko
    Pages 375-386
  14. Jeffrey Schlom, David Colcher, Diane E. Milenic, Patricia Horan Hand, John W. Greiner, Masahide Kuroki et al.
    Pages 387-416
  15. Fredrick J. Montz
    Pages 417-427
  16. Pentti Kuusela, Caj Haglund, Hannu Jalanko, Peter J. Roberts
    Pages 429-435
  17. Hiroshi Kato
    Pages 437-451
  18. Garri I. Abelev, Eleonora R. Karamova
    Pages 453-471
  19. Adolf L. Pohl
    Pages 473-494
  20. N. Coleman Owen
    Pages 495-523
  21. J. V. Klavins
    Pages 525-528
  22. Back Matter
    Pages 529-536

About this book


The purpose of this book-the fourth volume of a series on Can­ cer Markers-is intended to provide an updated "status report" on today's use of cancer markers in the diagnosis and monitoring of can­ cer, with an emphasis on cancer markers detected in the serum. It has been 7 years since the publication of the last volume in this series. The 1980, 1982, and 1985 volumes covered the development of cancer markers, not only in their roles of unraveling the basic biology of can­ cer, but also as increasingly important players in the management of patients with cancer. During the last 7 years we have seen the applica­ tion of a number of markers identified by monoclonal antibodies, as well as the beginnings of the use of genetic markers defined by mo­ lecular probes. Measurements of oncogenes in tissues or cells prom­ ise many applications for the future, but as yet, these genes have not shown to be useful as serum markers of cancer. The commercial interest in serum markers for cancer, particu­ larly for the diagnosis and monitoring of tumor patients, is indicated in Chapter 24 by Owen, where the total worldwide market for cancer markers is projected to increase from $148 million in 1988 to $232 million in 1993. The degree of research interest in cancer markers is reflected in the fact that in 1988 a separate category for tumor mark­ ers was added to Index Medicus.


antigen breast cancer cancer carcinoma cell embryo gastrointestinal cancer hormones leukemia lymphoma oncology tissue tumor

Editors and affiliations

  • Stewart Sell
    • 1
  1. 1.Department of Pathology and Laboratory MedicineUniversity of Texas Health Science CenterHoustonUSA

Bibliographic information

Industry Sectors
Health & Hospitals